Summary. Botulism, a food-borne toxin-mediated disease caused by Clostridium botulinum is still a common disease, which is most frequent in the rural environment; 108 cases, 66 males and 42 females, average age 32 years, were recorded from 1965 to 1990 in the infectious disease department of the University Hospital of Poitiers (France). In 83 % of patients, the food responsible was home-cured ham. Mean incubation time was 3-4 days; digestive symptoms were observed in 93% of cases, ocular symptoms in 92% and urinary tract dysfunction in 22 %. A scale of severity was used to classify the patients into those suffering from severe (6), intermediate (50) 
Introduction
Botulism is a widespread disease caused by the ingestion of a neurotropic exotoxin produced in contaminated food by Clostridium botulinum. It remains infrequent but is widely feared because it can be severe and is potentially lethal. The diagnosis can be straightforward but treatment is poorly defined. In the USA, 766 outbreaks representing 196 1 cases have been recorded in the last 77 years; 289 of these outbreaks have occurred between 1949 and 1976 and 355 cases were recorded between 1977 and 1984.'*2 The overall incidence of the disease in the USA is stable with 0.125 cases/ 100 000 population overall, but large regional variations occur with the highest incidence (8.4/100000) in Alaska.2 Many countries have also reported the highest incidence is in Poland and China. In France, the average number of cases reported varies from year to year but the epidemiological data are unreliable because of under-reporting : 22 cases were reported annually from 1966 to 1970, 70.8 cases from 1971 to 1978 and 28 cases from 1979 to 19W7 The mean incidence is estimated at 0.12 cases/ 100000 inhabitants.
The disease is more common in men than in women ; 60 % of patients in the USA are men with an average age of 40 years. 2 Biological confirmation of diagnosis can be obtained by detection of the toxin in serum or stool samples or by isolation of the causative organism from the food. Demonstration of the toxin can be done by an ELISA test or by seroneutralisation in mice, which is the standard reference method."
The treatment of botulism remains poorly standardised, particularly for the mild forms, which are by far the most common. Serotherapy is the only specific treatment but its use is controversial. An alternative treatment with guanidine has been proposed but, although its safety is well establi~hed,~' this treatment is not universally accepted because its effectiveness has not been clearly demonstrated.
In this retrospective report, we describe 108 cases of botulism from the University Hospital of Poitiers, seen over a 25-year period and treated with either serotherapy or guanidine. A scheme for evaluating severity based on the main clinical signs is proposed.
Patients and methods

Pat ien ts
The study comprised 108 patients admitted to the Infectious Diseases Department, University Hospital of Poitiers, between Jan. 1966 and Dec. 1990. The diagnosis of botulism was based on epidemiological data and on a clinical score of severity. The main clinical symptoms and signs found in botulism2+ were used to establish a clinical score of severity which permitted classification of the disease into three forms : mild, intermediate or severe (table I) . Each symptom or sign was scored for 1 point. The points numbers 1-7 defined the mild form (score < 3) and intermediate forms (score 4-7); the last two points defined severe forms (score 8-9, or any including the last two points). Five patients with known disorders that may have interfered with clinical evaluation were excluded from the study.
Methods
Botulinum toxin was detected in serum or suspected food by the mouse seroneutralisation test. Briefly, one part of the suspected food was homogenised with an equal volume of buffer (pH 6.8, containing agar, sterile water and disodium phosphate) and centrifuged at 2000 g for 15 min. The serum or supernate of homogenised food were separated into four parts of 2 ml each; three were neutralised with a specific equine antiserum (anti-A, -B or -E) and one was not neutralised. One ml of each sample was then injected intraperitoneally into a mouse. After 2-6 h, the mice inoculated with material containing un-neutralised botulinum toxin developed a paralytic disease and died within 24-36 h, the others survived without disease.
Results
Between Jan. 1966 and Dec. 1990,108 cases met the inclusion criteria. The patients comprised 66 (61 YO) males and 42 (39 YO) females aged 5-70 years (median 32 years). The suspected causative food was ham in 83% of cases and, in all but one case, the ham had been home-cured. The mean incubation period was 3.45 days (range 0.5-16 days, median 3.2 days) and the mean time to diagnosis was 7.11 days (range 3-32 days, median 6.1 days). According to the clinical criteria (table I), six (5.6 %) patients were classified as suffering from severe disease, 50 (46%) from intermediate disease and 52 (48 %) from a mild form.
Clinical features
The presenting symptoms (table 11) were restricted to the gastrointestinal tract in 41 cases (47%) and included diarrhoea, abdominal pain, nausea, vomiting and, sometimes, constipation. Ocular symptoms and dry mucosa syndrome (dryness of the mouth, dysphagia, dysphonia, drying of the lacrymal secretions) occurred first in 18 (17%) and 17 (16%) cases, respectively. In seven cases, both digestive and ocular symptoms and, in 15 cases, both digestive and dry mucosa syndrome, occurred together.
At the fully developed stage of disease (tables I1 and 111) dry mucosa syndrome was observed in 102 patients (95 YO), and was associated with dysphagia (95 cases, 88 YO), or deglutition problems (31 cases, 29 %).
Strawberry tongue, probably due to sicca syndrome, sometimes with thrush, was also observed (16 cases In one case, intestinal obstruction with fever occurred, but this resolved spontaneously. 
Toxin detection
In 100 cases, serum or food samples were examined for toxin (table IV) . Confirmation of the diagnosis was obtained in 67 patients by analysis of the suspect food (30 cases), or by the demonstration of circulating toxin (18 cases), or both (19 cases). The toxin identified was always of type B. Results of toxin assays in serum and food were concordant in 33 cases (both positive in 19 cases, both negative in 14 cases). The results from the examination of serum and food samples were discordant in 17 cases (serum positive and food negative in nine cases, serum negative and food positive in eight cases). In 17 cases multiple blood samples were obtained; in seven of these the toxin assay on the second sample gave negative results, but in 10 cases circulating toxin was found 5-43 days (mean 13.2 days) after the first determination. Five patients had received equine antitoxin between the first and the second assays; in two cases the result of the second assay for toxin was negative, in three cases it was positive.
Antiserum (with or without toxoid) Guanidine alone Guanidine and antiserum No treatment Total
(40)
(31) 31 (29) l(1) 108
Treatment
Urinary tract symptoms included dysuria or bladder paresis (19 cases, 18 %); seven cases of acute urinary retention required catheterisation. General symptoms consisted of asthenia and anorexia; fever was observed in only three cases.
In 10 cases, electromyography was performed; in three cases a presynaptic neuromuscular block was demonstrated.
Treatment of the 108 patients is summarised in table V. The antiserum was of equine origin, the toxoid was a formol-inactivated toxin and guanidine was used in a syrup form. Apart from some local reaction at the point of injection, no severe reactions were observed with the antiserum. There were signs of intolerance with the use of guanidine in two cases: psychomotor agitation in one case and muscular pain in the other. These side effects disappeared 48 h after reducing the dose. All patients recovered without sequelae. The mean time for resolution was 21 days from the time of admission. Only two patients had to be admitted to the intensive care unit and required ventilatory assistance, one for inhalation pneumonia and the other for respiratory muscular paralysis.
Additional measures required were : nursing care, suspension of oral feeding, parenteral nutrition or nutrition by gastro-duodenal tube, humidification of the buccal and pharyngeal mucosa by spraying, oral amphotericin B to prevent fungal infections, the use of artificial tears and prevention of decubitus complications.
Discussion
The 108 patients reported here represent only a proportion of the cases in our geographic area. The exact proportion cannot be known because some patients would have been hospitalised in other hospitals in the geographic area, and some patients with mild forms of botulism are not admitted to hospital. It appears that the diagnosis is often missed. Although the incidence of botulism in France is similar to that in the USA, certain regions such as PoitouCharentes stand out for their unusually high incidence. This may be related to traditional home-made food practices, e.g., hams are prepared without brine. It can be estimated that there is an average of 4.15 cases of botulism/year in the French department of the Vienne.
In our study, the observed clinical pictures agreed with published descriptions2* 4 7 [20] [21] [22] [23] (table 111) . The incubation period varied from 1 to 16 days. The initial period was short and characterised in > 50 YO of cases by digestive disorders followed by bilateral and symmetrical paralytic ocular manifestations associated with secretory problems. Oropharyngeal symptomsdysphagia, which may be total in severe disease, dysphonia and drying syndrome (dryness of the mouth, drying of salivary secretions, etc)-occurred most 2o Ocular symptoms-acute presbyopia caused by paralysis of accommodation, mydriasis, diplopia and dryness of lacrymal secretionwere almost as common.24 Persistent constipation, urinary tract disorders (dysuria and urine retention), serious respiratory problems caused by paralysis or deglutition dysfunction were less frequent ;21y 22 asthenia, arterial hypotension and vertigo, reported by several authors,20 were not observed in our patients.
Usual biological parameters revealed no specific or significant abnormalities. Electr om yograph y showed a presynaptic block which was neither constant nor specific4? 259 26 but which may be prognostically useful in severe forms of the disease. However, the results of laboratory tests did not change the therapy, which was based on the assessment by clinical examination.
Usually, the diagnosis of botulism was confirmed by demonstration and typing of toxin. Although other techniques, in particular ELISA, are currently being evaluated and appear promising,24 specific seroneutralisation in mice can be used for various types of sample and is the standard reference method. As botulism may be misdiagnosed as myasthenia gravis, specific seroneutralisation in mice can be complicated by pyridostigmine treatment of patients. 27 Toxaemia is generally demonstrated in c. 50 % of cases1' (52 YO in our series). Toxaemia persisted for 5-43 days after diagnosis in some cases, within which time patients had recovered from the disease. No tests were done for circulating antibodies against botulinum toxin. Toxaemia has been reported to persist for a variable time-up to several weeks17-raising the question of chronic carriage of the organism or of re-infection. This finding does not appear in reports from the USA, possibly due to treatment of patients with antitoxin or to differences between toxin types-non-proteolytic type B in France but proteolytic type A and B in the USA. Culture for C. botulinurn in stool samples may be useful and is positive in c. 70 YO of cases.28
Botulism is a serious intoxication that is potentially lethal. The course of the disease is often complicated by infections of the oropharhynx or respiratory tract, and by paralysis of respiratory muscles which may require assisted ventilation.22g 29 Cases of botulism caused by type A or E toxin seem to be more severe than those caused by type B. However, although the severity of disease and the number of complications are greater with type A toxin, there is no difference between toxins A and B in terms of mortality2. Disease caused by type E toxin has a reputation for being particularly serious; 53% of deaths reported by Wainwright et aL2 were due to type E botulism, but 73 % of the cases in that study were due to type E. In France, two fatal cases were reported in 1987 and 1988 with type B C. b o t~l i n u m .~
The prognosis of botulism may be also influenced by the length of the incubation period2 and-although these factors are not universally accepted-by age, race (the disease may be more severe in Asian people), early involvement of the third cranial nerves and paralysis of the respiratory muscles.22*23 There were no deaths in our series; this may be due to the frequency of the mild forms of the disease (reflected by the unusually long incubation period), and the usually good prognosis of type B botulism in France.
Approaches to the treatment of botulism remain debatable. All authors agree that symptomatic care is essential, including artificial tears, spraying and humidification of the oropharynx and airways, and feeding by gastric tube or parental nutrition. Specific treatment is more controversial, particularly in relation to the adequacy and effectiveness of serotherapy. The use of botulinum toxoid is of doubtful value for treating botulism," because the time required to achieve an immunological response is too long. Equine serum may be given parentally at 0.5 ml/kg (for type B, 1 ml = 250 IU). It should be reserved for severe forms of the disease in which it needs to be used at an early stage to be e f f e~t i v e . '~.~~ However, waiting to determine whether a case is severe or mild before deciding to administer antiserum could compromise its usefulness; severity must be determined by simple clinical examination. The duration of treatment remains debatable; most authors advocate treating until there is no further progression of symptoms.20 Serotherapy may prevent progression of neurological symptoms and may shorten the time of respiratory distress and assisted ventilation in type E botu1ism.l' The level of circulating antitoxin measured after administration (in four patients) appeared to reduce the rate of circulating type A, B or E toxin.30 There may not be any advantage in giving more than two doses of antitoxin.30 There is no evidence that it is necessary to clear circulating toxin in mild forms of the disease. The value of serotherapy in the intermediate or mild forms of type B botulism seen in France has not been established, particularly because the use of heterologous serum is not without risk.
Concern about serotherapy and its side effects led Cherrington and Ryanlg to propose, in 1968, the use of guanidine given orally at 10-35 mg/kg daily, in four doses. Guanidine antagonises the effects of botulinum toxin at the neuromuscular junction. They obtained beneficial results in 34 of 52 cases. 19 The effectiveness
